Posted On: 04/27/2016 10:03:36 AM
Post# of 77
Yesterday was a huge day for many SUMMIT THERAPEUTICS! This is a company with huge potential. The FDA has cleared its Investigational New Drug (IND) application for DMD candidate ezutromid (formerly SMT C1100) which clears the way to recruit U.S. trial sites in its Phase 2 proof-of-concept study called PhaseOut DMD.
Renowned English scientist Dame Kay Davis and her Oxford University team have been working on this for donkey's years.
Yesterday as Sarepta (following Biomarin) had a bad day and as a consequence of their DMD approach, they fell from grace ... suddenly for the first time investors started to look at Summit who now lead the way.
Unlike Sarepta's eteplirsen or BioMarin Pharmaceutical's (NASDAQ:BMRN) drisapersen, which are restricted to DMD amenable to skipping exon 51 (~13% of DMD cases), ezutromid has the potential to treat all boys and young men with DMD. It modulates utrophin, a protein functionally and structurally similar to dystrophin, a protein that helps keep muscle cells intact and whose absence causes DMD.
Also they have recently cleared Phase Two trials with another success story .. a cure for C Diff that is now best in class. Clostridium difficile, or C-diff, is caused after damage to the microbiome but patients can get a double whammy, as using broad spectrum antibiotics can further damage the microbiome.
Summit findings show a reduced recurrence rate and a superior rate of sustained clinical response in patients with C-diff receiving its treatment ridinilazole, compared with those receiving the current standard of care, vancomycin.
Not one but two potential drugs with multi-billion dollar markets.
Renowned English scientist Dame Kay Davis and her Oxford University team have been working on this for donkey's years.
Yesterday as Sarepta (following Biomarin) had a bad day and as a consequence of their DMD approach, they fell from grace ... suddenly for the first time investors started to look at Summit who now lead the way.
Unlike Sarepta's eteplirsen or BioMarin Pharmaceutical's (NASDAQ:BMRN) drisapersen, which are restricted to DMD amenable to skipping exon 51 (~13% of DMD cases), ezutromid has the potential to treat all boys and young men with DMD. It modulates utrophin, a protein functionally and structurally similar to dystrophin, a protein that helps keep muscle cells intact and whose absence causes DMD.
Also they have recently cleared Phase Two trials with another success story .. a cure for C Diff that is now best in class. Clostridium difficile, or C-diff, is caused after damage to the microbiome but patients can get a double whammy, as using broad spectrum antibiotics can further damage the microbiome.
Summit findings show a reduced recurrence rate and a superior rate of sustained clinical response in patients with C-diff receiving its treatment ridinilazole, compared with those receiving the current standard of care, vancomycin.
Not one but two potential drugs with multi-billion dollar markets.
(3)
(0)
